HEMOGENYX PHARMPLC (Germany) Performance
| 5HU Stock | EUR 4.14 0.62 13.03% |
HEMOGENYX PHARMPLC holds a performance score of 9 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -25.61, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning HEMOGENYX PHARMPLC are expected to decrease by larger amounts. On the other hand, during market turmoil, HEMOGENYX PHARMPLC is expected to outperform it. Use HEMOGENYX PHARMPLC LS 01 downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to analyze future returns on HEMOGENYX PHARMPLC LS 01.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in HEMOGENYX PHARMPLC LS 01 are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, HEMOGENYX PHARMPLC reported solid returns over the last few months and may actually be approaching a breakup point. ...more
HEMOGENYX |
HEMOGENYX PHARMPLC Relative Risk vs. Return Landscape
If you would invest 420.00 in HEMOGENYX PHARMPLC LS 01 on September 19, 2024 and sell it today you would lose (6.00) from holding HEMOGENYX PHARMPLC LS 01 or give up 1.43% of portfolio value over 90 days. HEMOGENYX PHARMPLC LS 01 is currently producing 16.1686% returns and takes up 127.5355% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than HEMOGENYX, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
HEMOGENYX PHARMPLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HEMOGENYX PHARMPLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HEMOGENYX PHARMPLC LS 01, and traders can use it to determine the average amount a HEMOGENYX PHARMPLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1268
| Best Portfolio | Best Equity | 5HU | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 127.54 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average HEMOGENYX PHARMPLC is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HEMOGENYX PHARMPLC by adding it to a well-diversified portfolio.
HEMOGENYX PHARMPLC Fundamentals Growth
HEMOGENYX Stock prices reflect investors' perceptions of the future prospects and financial health of HEMOGENYX PHARMPLC, and HEMOGENYX PHARMPLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HEMOGENYX Stock performance.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Shares Outstanding | 979.75 M | |||
| EBITDA | (2.62 M) | |||
| Cash And Equivalents | 1.81 M | |||
| Total Debt | 1.63 M | |||
| Debt To Equity | 1.86 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.01) X | |||
About HEMOGENYX PHARMPLC Performance
By analyzing HEMOGENYX PHARMPLC's fundamental ratios, stakeholders can gain valuable insights into HEMOGENYX PHARMPLC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HEMOGENYX PHARMPLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HEMOGENYX PHARMPLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was incorporated in 2013 and is headquartered in London, the United Kingdom. HEMOGENYX PHARM is traded on Frankfurt Stock Exchange in Germany.Things to note about HEMOGENYX PHARMPLC performance evaluation
Checking the ongoing alerts about HEMOGENYX PHARMPLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HEMOGENYX PHARMPLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HEMOGENYX PHARMPLC is way too risky over 90 days horizon | |
| HEMOGENYX PHARMPLC appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (2.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| HEMOGENYX PHARMPLC LS 01 has accumulated about 1.81 M in cash with (1.8 M) of positive cash flow from operations. | |
| Roughly 15.0% of the company shares are owned by insiders or employees |
- Analyzing HEMOGENYX PHARMPLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HEMOGENYX PHARMPLC's stock is overvalued or undervalued compared to its peers.
- Examining HEMOGENYX PHARMPLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HEMOGENYX PHARMPLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HEMOGENYX PHARMPLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HEMOGENYX PHARMPLC's stock. These opinions can provide insight into HEMOGENYX PHARMPLC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HEMOGENYX Stock analysis
When running HEMOGENYX PHARMPLC's price analysis, check to measure HEMOGENYX PHARMPLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HEMOGENYX PHARMPLC is operating at the current time. Most of HEMOGENYX PHARMPLC's value examination focuses on studying past and present price action to predict the probability of HEMOGENYX PHARMPLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HEMOGENYX PHARMPLC's price. Additionally, you may evaluate how the addition of HEMOGENYX PHARMPLC to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |